Lorenzini Apparels Ltd. Share Price

Canara Bank Ltd Q2 FY27 provisional business update

Dr Lal PathLabs buys 80% Ghana stake for ₹38 crore

Dr Lal PathLabs completed the acquisition of an 80% stake in Ghana-based Sunshine Healthcare for approximately ₹38 crore. This establishes a new step-down subsidiary to drive its West African diagnostic expansion. The transaction, routed through its Dubai subsidiary, adds a new international revenue stream alongside a recent 70% stake acquisition in Uzbekistan. This matters as it diversifies revenue away from India's highly competitive domestic diagnostic market, backed by a robust ₹1,693 crore cash reserve and a 19.1% YoY Q1 FY27 revenue growth to ₹798 crore. I am watching the Q3 FY27 earnings call for the first consolidated revenue contribution from the Ghana entity and management's commentary on the Uzbekistan integration timeline. The market currently prices Dr Lal PathLabs purely on its domestic market share battles against aggressive tech-led aggregators and standalone labs. What the consensus is missing is the structural valuation re-rating that comes from successful international diversification. At just ₹38 crore, this acquisition is a low-risk, high-optionality probe into West Africa, not a balance sheet strain. By routing this through its Dubai entity, the company optimizes its global tax structure while testing emerging market dynamics. The real catalyst is not the immediate top-line addition, but the proof of concept: if the Ghana and Uzbekistan models yield EBITDA margins comparable to its domestic 31.0%, it unlocks a replicable, capital-light playbook for emerging markets that the market currently does not price into the stock. Accumulate for long-term international margin diversification. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice.

Dr Lal PathLabs To Acquire 70% Stake In SN Genelab

Uttam Sugar Mills reported weak Q2 FY26 results yesterday

Dr Lal PathLabs Just Made A ₹168 Crore Acquisition Move

Dr Lal PathLabs is in focus today after announcing the acquisition of a 70% stake in SN Genelab. !LALPATHLAB The deal is valued at up to ₹168 crore in cash, with an additional earn-out of up to ₹31.5 crore. But the interesting part isn't just the amount being spent. It's what Dr Lal is actually buying. SN Genelab operates in genomics, molecular diagnostics, cancer diagnostics and cytogenetics. So this acquisition is essentially about expanding into more specialised diagnostic services. And this is where acquisition news becomes interesting for investors. A company doesn't acquire another business just to add its revenue. Ideally, it should add something strategic. New capabilities. New customers. New geographical presence. Or access to a faster-growing segment. In this case, Dr Lal PathLabs said the acquisition will strengthen its genomics and specialised diagnostics portfolio and expand its presence in western India. SN Genelab has also reported strong growth over the past few years. Its revenue CAGR was around 24% between FY21 and FY26, while EBITDA CAGR was around 31%. But here's the important part. Past growth doesn't automatically guarantee future growth. The real test starts after the acquisition. Can Dr Lal integrate the business successfully? Can it scale the specialised diagnostics offering? Can the additional capabilities improve overall profitability? And what return will the company eventually generate on the ₹168 crore investment? This is why I think investors should look beyond the headline: “Company acquires 70% stake.” The better question is: What strategic problem is this acquisition solving? Because a good acquisition isn't simply about buying another company. It's about whether the acquired business can become more valuable inside the larger organisation. That's the part I'll be watching. And it's a useful lesson wheneve

Dr. Lal PathLabs to acquire 70% of SN Genelab

Dr. Lal PathLabs Limited (